Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (...
The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023 Stelara® (ustekinumab) is prescribed to treat a variety of inflammatory conditions REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 06, …